• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 8, 2022
Discovery & Translation

Young companies taking on checkpoint inhibitor resistance at AACR22

Ten companies you may not have heard of tackling checkpoint resistance at AACR22
Read More
BioCentury | Feb 7, 2022
Discovery & Translation

Translational trendspotting: a Distillery dive into cancer

BioCentury’s Distillery highlights white space cancer targets, new protein degraders and strategies to boost T cell responses to tumors
Read More
BioCentury | Oct 27, 2021
Distillery Therapeutics

Targeting LRG1 after surgery for solid tumor metastasis

Read More
BioCentury | Sep 15, 2014
Company News

Abzena, UCL deal

Read More
Items per page:
1 - 4 of 4